Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes: SGLT2 inhibitors in elderly and real life
[en] Patients with type 2 diabetes mellitus (T2DM) are exposed to a high risk of atherosclerotic cardiovascular disease, heart failure and chronic kidney disease. The incidence of these complications increases markedly with the duration of diabetes and aging. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) showed a remarkable reduction in hospitalization for heart failure and progression of kidney disease in large prospective placebo-controlled trials. Post hoc analyses of these trials demonstrated that cardiorenal protection occurred independently of age. The present comprehensive review analyzes the effects of SGLT2is on cardiovascular and renal outcomes among older patients with T2DM in cohort studies and real-life conditions. SGLT2is were associated with a significant reduction in hospitalization for heart failure (alone or combined with mortality) and in a composite renal outcome, including end-stage renal disease when compared to other oral glucose-lowering drugs, dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists in patients aged ≥ 65 years and even ≥ 75 years. Several observational studies worldwide compared cardiorenal outcomes in people aged ≥ 65 years versus < 65 years and showed a similar relative benefit of SGLT2is in older versus younger patients with T2DM. These favourable results were obtained while the safety profile of SGLT2is in older patients was acceptable and almost comparable with that reported in younger patients. In conclusion, observational studies in real-life conditions confirm previous results reported in placebo-controlled trials and a positive benefit/risk balance in elderly patients with T2DM at risk of heart failure and chronic kidney disease.
Scheen, André ; Centre Hospitalier Universitaire de Liège - CHU > > Service de diabétologie, nutrition, maladies métaboliques
Language :
English
Title :
Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes: SGLT2 inhibitors in elderly and real life
scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.
Bibliography
ElSayed, N.A., Aleppo, G., Aroda, V.R., et al. 10. Cardiovascular disease and risk management: standards of care in diabetes-2023. Diabetes Care 46:Suppl 1 (2023), S158–SS90.
Kenny, H.C., Abel, E.D., Heart failure in type 2 diabetes mellitus. Circ Res 124 (2019), 121–141.
Kidney Disease: Improving Global Outcomes Diabetes Work G. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 102:5S (2022), S1–S127.
Scheen, A.J., Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus. Nature Rev Endocrinol 16 (2020), 556–577.
Giugliano, D., Longo, M., Scappaticcio, L., et al. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs. Cardiovasc Diabetol, 20, 2021, 236.
Usman, M.S., Khan, M.S., Fonarow, G.C., et al. Robustness of outcomes in trials evaluating sodium-glucose co-transporter 2 inhibitors for heart failure. ESC Heart Fail 9 (2022), 885–893.
Scheen, A.J., Counteracting heart failure with diabetes drugs: a review into the pharmacokinetic and pharmacodynamic properties. Expert Opin Drug Metab Toxicol 18 (2022), 381–393.
Neuen, B.L., Young, T., Heerspink, H.J.L., et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 7 (2019), 845–854.
Bailey, C.J., Day, C., Bellary, S., Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease. Curr Diab Rep 22 (2022), 39–52.
Scheen, A.J., Bonnet, F., Efficacy and safety profile of SGLT2 inhibitors in the elderly: how is the benefit/risk balance?. Diabetes Metab, 49, 2023, 101419.
Sridhar, V.S., Rahman, H.U., Cherney, D.Z.I., What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?. Diabetes Obes Metab 22:Suppl 1 (2020), 55–68.
Fadini, G.P., Del Prato, S., Avogaro, A., et al. Challenges and opportunities in real-world evidence on the renal effects of sodium-glucose cotransporter-2 inhibitors. Diabetes Obes Metab 24 (2022), 177–186.
Han, S.J., Ha, K.H., Lee, N., et al. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a nationwide population-based study. Diabetes Obes Metab 23 (2021), 682–691.
Heerspink, H.J.L., Karasik, A., Thuresson, M., et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol 8 (2020), 27–35.
Fralick, M., Colacci, M., Thiruchelvam, D., et al. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a nationwide cohort study of older adults with diabetes mellitus. Diabetes Obes Metab 23 (2021), 950–960.
Nakai, M., Iwanaga, Y., Kanaoka, K., et al. Contemporary use of SGLT2 inhibitors in heart failure patients with diabetes mellitus: a comparison of DPP4 inhibitors in a nationwide electric health database of the superaged society. Cardiovasc Diabetol, 21, 2022, 157.
Htoo, P.T., Tesfaye, H., Schneeweiss, S., et al. Comparative effectiveness of empagliflozin vs liraglutide or sitagliptin in older adults with diverse patient characteristics. JAMA Netw Open, 5, 2022, e2237606.
Desai, R.J., Glynn, R.J., Everett, B.M., et al. Comparative effectiveness of empagliflozin in reducing the burden of recurrent cardiovascular hospitalizations among older adults with diabetes in routine clinical care. Am Heart J 254 (2022), 203–215.
Patorno, E., Pawar, A., Bessette, L.G., et al. Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists in older adults. Diabetes Care 44 (2021), 826–835.
Schechter, M., Melzer-Cohen, C., Rozenberg, A., et al. Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence. Cardiovasc Diabetol, 20, 2021, 169.
Baviera, M., Foresta, A., Colacioppo, P., et al. Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study. Cardiovasc Diabetol, 21, 2022, 162.
Gonzalez Perez, A., Vizcaya, D., Saez, M.E., et al. Cardiovascular and renal outcomes among patients with type 2 diabetes using SGLT2 inhibitors added to metformin: a population-based cohort study from the UK. BMJ Open Diabetes Res Care, 11, 2023, e003072.
Birkeland, K.I., Jorgensen, M.E., Carstensen, B., et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol 5 (2017), 709–717.
Gautam, S., Agiro, A., Barron, J., et al. Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis. Cardiovasc Diabetol, 16, 2017, 93.
Pasternak, B., Ueda, P., Eliasson, B., et al. Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: scandinavian register based cohort study. BMJ, 366, 2019, l4772.
Dawwas, G.K., Smith, S.M., Park, H., Cardiovascular outcomes of sodium glucose cotransporter-2 inhibitors in patients with type 2 diabetes. Diabetes Obes Metab 21 (2019), 28–36.
Yang, C.T., Peng, Z.Y., Chen, Y.C., et al. Cardiovascular benefits with favorable renal, amputation and hypoglycemic outcomes of SGLT-2 inhibitors in type 2 diabetes from the Asian perspective: a population-based cohort study and systematic review. Front Endocrinol (Lausanne), 13, 2022, 836365.
Seino, Y., Kim, D.J., Yabe, D., et al. Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: results from the EMPRISE East Asia study. Endocrinol Diabetes Metab, 4, 2021, e00183.
Patorno, E., Pawar, A., Wexler, D.J., et al. Effectiveness and safety of empagliflozin in routine care patients: results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study. Diabetes Obes Metab 24 (2022), 442–454.
Filion, K.B., Lix, L.M., Yu, O.H., et al. Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study. BMJ, 370, 2020, m3342.
Peng, Z.Y., Yang, C.T., Kuo, S., et al. Restricted mean survival time analysis to estimate SGLT2i-associated heterogeneous treatment effects on primary and secondary prevention of cardiorenal outcomes in patients with type 2 diabetes in Taiwan. JAMA Netw Open, 5, 2022, e2246928.
Idris, I., Zhang, R., Mamza, J.B., et al. Lower risk of hospitalisation for heart failure, kidney disease and death with sodium glucose co-transporter-2 compared to dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: a retrospective cohort study in UK primary care. Diabetes Obes Metab 23 (2021), 2207–2214.
Giugliano, D., Longo, M., Maiorino, M.I., et al. Efficacy of SGLT-2 inhibitors in older adults with diabetes: systematic review with meta-analysis of cardiovascular outcome trials. Diabetes Res Clin Pract, 162, 2020, 108114.
Amioka, M., Sanada, R., Matsumura, H., et al. Impact of SGLT2 inhibitors on old age patients with heart failure and chronic kidney disease. Int J Cardiol 370 (2023), 294–299.
Voors, A.A., Angermann, C.E., Teerlink, J.R., et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med 28 (2022), 568–574.
Perez-Belmonte, L.M., Sanz-Canovas, J., Millan-Gomez, M., et al. Clinical benefits of empagliflozin in very old patients with type 2 diabetes hospitalized for acute heart failure. J Am Geriatr Soc 70 (2022), 862–871.
Jeong, S.J., Lee, S.E., Shin, D.H., et al. Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study. BMC Nephrol, 22, 2021, 177.
Takeuchi, M., Ogura, M., Minoura, T., et al. Comparative effectiveness of sodium-glucose cotransporter-2 inhibitors versus other classes of glucose-lowering medications on renal outcome in type 2 diabetes. Mayo Clin Proc 95 (2020), 265–273.
Koh, E.S., Han, K., Nam, Y.S., et al. Renal outcomes and all-cause death associated with sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL 3 Korea). Diabetes Obes Metab 23 (2021), 455–466.
Nagasu, H., Yano, Y., Kanegae, H., et al. Kidney outcomes associated with SGLT2 inhibitors versus other glucose-lowering drugs in real-world clinical practice: the Japan chronic kidney disease database. Diabetes Care 44 (2021), 2542–2551.
Pasternak, B., Wintzell, V., Melbye, M., et al. Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: scandinavian cohort study. BMJ, 369, 2020, m1186.
Park, G., Choi, B., Kang, S., et al. Sodium-glucose cotransporter-2 inhibitors could help delay renal impairment in patients with type 2 diabetes: a real-world clinical setting. J Clin Med, 11, 2022, 5259.
Au, P.C.M., Tan, K.C.B., Cheung, B.M.Y., et al. Association between SGLT2 inhibitors vs DPP4 inhibitors and renal outcomes among patients with type 2 diabetes. J Clin Endocrinol Metab 107 (2022), e2962–e2e70.
Lui, D.T.W., Au, I.C.H., Tang, E.H.M., et al. Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: a real-world population-based analysis. EClinicalMedicine, 50, 2022, 101510.
Kobayashi, K., Toyoda, M., Hatori, N., et al. Comparison of renal outcomes between sodium glucose co-transporter 2 inhibitors and glucagon-like peptide 1 receptor agonists. Diabetes Res Clin Pract, 185, 2022, 109231.
Deng, Y., Ghamsari, F., Lu, A., et al. Use of real-world evidence data to evaluate the comparative effectiveness of second-line type 2 diabetes medications on chronic kidney disease. J Clin Transl Endocrinol, 30, 2022, 100309.
Zhang, X., Zhong, Z., Li, Y., et al. Long-term renal outcomes associated with sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Metab Res Rev, 36, 2020, e3303.
Kaze, A.D., Zhuo, M., Kim, S.C., et al. Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis. Cardiovasc Diabetol, 21, 2022, 47.
Li, N., Lv, D., Zhu, X., et al. Effects of SGLT2 inhibitors on renal outcomes in patients with chronic kidney disease: a meta-analysis. Front Med, 8, 2021, 728089.
Nuffield Department of Population Health Renal Studies G. Consortium SiM-AC-RT. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 400 (2022), 1788–1801.
Yi, T.W., Atiquzzaman, M., Zheng, Y., et al. Findings of sodium-glucose cotransporter-2 inhibitor kidney outcome trials applied to a Canadian chronic kidney disease population: a retrospective cohort study. Can J Kidney Health Dis, 9, 2022, 20543581221145068.
Scheen, A.J., Delanaye, P., Acute renal injury events in diabetic patients treated with SGLT2 inhibitors: a comprehensive review with a special reference to RAAS blockers. Diabetes Metab, 48, 2022, 101315.
Delanaye, P., Scheen, A.J., Epidemiology of acute kidney injury adverse events with SGLT2 inhibitors: a meta-analysis of observational cohort studies. Diabetes Epidemiol Manag, 3, 2021, 100021.
Zhuo, M., Paik, J.M., Wexler, D.J., et al. SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes. Am J Kidney Dis 79 (2022), 858–867 e1.
Lee, Y.T., Hsu, C.N., Fu, C.M., et al. Comparison of adverse kidney outcomes with empagliflozin and linagliptin use in patients with type 2 diabetic patients in a real-world setting. Front Pharmacol, 12, 2021, 781379.
Adams, J., Mosler, C., Safety and efficacy considerations amongst the elderly population in the updated treatment of heart failure: a review. Expert Rev Cardiovasc Ther 20 (2022), 529–541.
Scheen, A.J., An update on the safety of SGLT2 inhibitors. Expert Opin Drug Safety 18 (2019), 295–311.
Inagaki, N., Nangaku, M., Sakata, Y., et al. Real-world safety and effectiveness of canagliflozin treatment for type 2 diabetes mellitus in Japan: SAPPHIRE, a long-term, large-scale post-marketing surveillance. Adv Ther 39 (2022), 674–691.
Scheen, A.J., Careful use to minimize adverse events of oral antidiabetic medications in the elderly. Expert Opin Pharmacother 22 (2021), 2149–2165.
American Diabetes Association Professional Practice Committee Draznin, B., Aroda, V.R., et al. 13. Older adults: standards of medical care in diabetes-2022. Diabetes Care 45:Suppl 1 (2022), S195–S207.
Pollack, R., Cahn, A., SGLT2 inhibitors and safety in older patients. Heart Fail Clin 18 (2022), 635–643.
Sinclair, A., Bode, B., Harris, S., et al. Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. BMC Endocr Disord, 14, 2014, 37.
Sinclair, A.J., Bode, B., Harris, S., et al. Efficacy and safety of canagliflozin in individuals aged 75 and older with type 2 diabetes mellitus: a pooled analysis. J Am Geriatr Soc 64 (2016), 543–552.
Fioretto, P., Mansfield, T.A., Ptaszynska, A., et al. Long-term safety of dapagliflozin in older patients with type 2 diabetes mellitus: a pooled analysis of phase IIb/III studies. Drugs Aging 33 (2016), 511–522.
Kohler, S., Zeller, C., Iliev, H., et al. Safety and tolerability of empagliflozin in patients with type 2 diabetes: pooled analysis of phase I-III clinical trials. Adv Ther 34 (2017), 1707–1726.
Pratley, R., Dagogo-Jack, S., Charbonnel, B., et al. Efficacy and safety of ertugliflozin in older patients with type 2 diabetes: a pooled analysis of phase III studies. Diabetes Obes Metab 22 (2020), 2276–2286.
Similar publications
Sorry the service is unavailable at the moment. Please try again later.
This website uses cookies to improve user experience. Read more
Save & Close
Accept all
Decline all
Show detailsHide details
Cookie declaration
About cookies
Strictly necessary
Performance
Strictly necessary cookies allow core website functionality such as user login and account management. The website cannot be used properly without strictly necessary cookies.
This cookie is used by Cookie-Script.com service to remember visitor cookie consent preferences. It is necessary for Cookie-Script.com cookie banner to work properly.
Performance cookies are used to see how visitors use the website, eg. analytics cookies. Those cookies cannot be used to directly identify a certain visitor.
Used to store the attribution information, the referrer initially used to visit the website
Cookies are small text files that are placed on your computer by websites that you visit. Websites use cookies to help users navigate efficiently and perform certain functions. Cookies that are required for the website to operate properly are allowed to be set without your permission. All other cookies need to be approved before they can be set in the browser.
You can change your consent to cookie usage at any time on our Privacy Policy page.
